MUMBAI, India, Aug. 29 -- Intellectual Property India has published a patent application (202517075531 A) filed by Redx Pharma Limited, Macclesfield, U.K., on Aug. 8, for 'ddr1 and ddr2 inhibitors having a dihydrobenzimidazolone core.'
Inventor(s) include Guisot, Nicolas E. S.; Bhamra, Inder; Jones, Clifford D.; Ryan, James; Andr, Michal; Varela Rodrguez, Ana; and Gignoux, Camille.
The application for the patent was published on Aug. 29, under issue no. 35/2025.
According to the abstract released by the Intellectual Property India: "This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and discoidin domain receptor 2 (DDR2). The compounds are particularly useful in the treatment of cancer and fibrotic diseases."
The patent application was internationally filed on Feb. 15, 2024, under International application No.PCT/GB2024/050413.
Disclaimer: Curated by HT Syndication.
